A comparative analysis of registered and imported nootropic drugs in the pharmaceutical market in the Republic of Uzbekistan
DOI:
https://doi.org/10.24959/sphhcj.25.373Keywords:
assortment analysis; nootropic drugs; pharmaceutical market volume; comparative analysis; natural indicatorAbstract
Nootropic drugs are widely used to treat cognitive impairments associated with attention deficit hyperactivity disorder, dementia, Alzheimer’s disease, schizophrenia, and cerebrovascular disorders, including stroke. The growing prevalence of neurodegenerative diseases, aging population, and increased neuropsychological stress have led to a sustained rise in demand for nootropic therapy. Under these conditions, assessing the relationship between the drug registration and the actual market availability is essential for evaluating the effectiveness of pharmaceutical supply.
Aim. To conduct a comparative analysis of the range of nootropic drugs registered in the State Register of Medicines of the Republic of Uzbekistan and the actual volume of these drugs introduced into the national pharmaceutical market over the period of 2014–2024.
Materials and methods. Comparative, systematic, economic, and statistical methods, well as marketing research and content analysis were used in the study. Data were obtained from the State Register of Medicines, Drug Audit reports, and the reference database. The analysis covered the number of registered and marketed trade names, countries of origin, manufacturers, international nonproprietary names, dosage forms, and the physical market volume expressed in packages.
Results and discussion. The results showed an almost twofold increase in the number of the registered nootropic drugs during the study period. However, only 40–55 % of the drugs registered actually entered the market, indicating a steady gap between the regulatory approval and commercialization. Since 2021, the share of domestic nootropic drugs has increased significantly, reflecting the strengthening of national pharmaceutical production. Monocomponent drugs continued to dominate the range although the share of multicomponent drugs increased. Injectable solutions accounted for the largest share of both the registered drugs and the market volume, while oral dosage forms showed a gradual growth. Piracetam and Citicoline remain the leading names although recent years have been characterized by increasing diversification towards peptide complexes and combination drugs.
Conclusions. The study provides a comprehensive overview of the structure and dynamics of the nootropic drug market in Uzbekistan and can be useful for making evidence-based decisions in pharmaceutical regulation, production planning, and market strategy development.
References
Malík, M., & Tlustoš, P. (2022). Nootropics as Cognitive Enhancers: Types, Dosage and Side Effects of Smart Drugs. Nutrients, 14(16), 3367. https://doi.org/10.3390/nu14163367
Schifano, F., Bonaccorso, S., Arillotta, D., Corkery, J. M., Floresta, G., Papanti Pelletier, G. D., & Guirguis, A. (2025). Focus on Cognitive Enhancement: A Narrative Overview of Nootropics and “Smart Drug” Use and Misuse. Biology, 14(9), 1244. https://doi.org/10.3390/biology14091244
Teleanu, R. I., Niculescu, A. G., Roza, E., Vladâcenco, O., Grumezescu, A. M., & Teleanu, D. M. (2022). Neurotransmitters-Key Factors in Neurological and Neurodegenerative Disorders of the Central Nervous System. International journal of molecular sciences, 23(11), 5954. https://doi.org/10.3390/ijms23115954
Burtscher, J., Niedermeier, M., Hüfner, K., van den Burg, E., Kopp, M., Stoop, R., Burtscher, M., Gatterer, H., & Millet, G. P. (2022). The interplay of hypoxic and mental stress: Implications for anxiety and depressive disorders. Neuroscience and biobehavioral reviews, 138, 104718. https://doi.org/10.1016/j.neubiorev.2022.104718
Dementia. WHO. https://www.who.int/news-room/fact-sheets/detail/dementia
Fasoro, O. S., Anyanwu, F. C., Jayeola, A. O., Okobi, O. E., Osaigbovo, J. O., Onojedje, A. C., Balogun, R. O., Abah, O. C., Okoro, A., & Okeke-Chikelu, C. (2025). Incidence of Dementia in Canada: A National Trend Analysis of Newly Diagnosed Cases. Cureus, 17(8), e90418. https://doi.org/10.7759/cureus.90418
Pang, K., Jiang, R., Zhang, W., Yang, Z., Li, L. L., Shimozawa, M., Tambaro, S., Mayer, J., Zhang, B., Li, M., Wang, J, Liu, H., Yang, A., Chen, X., Liu, J., Winblad, B., Han, H., Jiang, T., Wang, W. . . . Lu, B. (2022). An App knock-in rat model for Alzheimer’s disease exhibiting Aβ and tau pathologies, neuronal death and cognitive impairments. Cell Research, 32(2), 157–175. https://doi.org/10.1038/s41422-021-00582-x
Della Rocca, Y., Fonticoli, L., Rajan, T. S., Trubiani, O., Caputi, S., Diomede, F., Pizzicannella, J., & Marconi, G. D. (2022). Hypoxia: molecular pathophysiological mechanisms in human diseases. Journal of physiology and biochemistry, 78(4), 739–752.
World Life Expectancy. Uzbekistan country health profile. (2025, December 01). https://www.worldlifeexpectancy.com/country-health-profile/uzbekistan
Statistics on the incidence of Alzheimer’s disease in the Republic of Uzbekistan. (2024). Ministry of Health of the Republic of Uzbekistan. https://www.worldlifeexpectancy.com/uzbekistan-alzheimers-dementia
Saydalieva, D. U., Sultanbaeva, N. M. U., & Umarova, Sh. Z. (2023). Assortment analysis of nootropic drugs registered in the Republic of Uzbekistan for 2018–2022. Journal of Pharmacy and Pharmacology, (3), 71–78.
Saydalieva, D., & Sultanbaeva, N. (2025). Trends in the nootropic drugs market in the republic of Uzbekistan. Social Pharmacy in Health Care, 11(2), 64–72. https://doi.org/10.24959/sphhcj.25.353
Saydalieva, D. U., & Sultanbaeva, N. M. U. (2023). ABC–XYZ analysis of nootropic drugs in the Republic of Uzbekistan for 2018–2022. Journal of Pharmacy and Pharmacology, (4), 82–87.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
